Youcare Pharmaceutical Group Co Ltd banner

Youcare Pharmaceutical Group Co Ltd
SSE:688658

Watchlist Manager
Youcare Pharmaceutical Group Co Ltd Logo
Youcare Pharmaceutical Group Co Ltd
SSE:688658
Watchlist
Price: 19.8 CNY 5.49% Market Closed
Market Cap: ¥8.9B

Youcare Pharmaceutical Group Co Ltd
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Youcare Pharmaceutical Group Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Youcare Pharmaceutical Group Co Ltd
SSE:688658
Total Receivables
¥646m
CAGR 3-Years
-23%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
¥3.1B
CAGR 3-Years
-5%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
¥6.3B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
6%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
¥13.4B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
11%
Zhejiang Nhu Co Ltd
SZSE:002001
Total Receivables
¥4.4B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
¥255m
CAGR 3-Years
16%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
No Stocks Found

Youcare Pharmaceutical Group Co Ltd
Glance View

Market Cap
8.9B CNY
Industry
Pharmaceuticals

Youcare Pharmaceutical Group Co Ltd has woven itself into the fabric of China’s pharmaceutical industry, standing out with its dedication to research, production, and distribution of a diverse array of healthcare products. Founded with the vision of improving health outcomes, Youcare Pharmaceuticals has strategically positioned itself within the highly competitive pharmaceutical landscape by investing heavily in innovation and quality control. With a robust R&D wing, the company channels significant resources into developing new medications and improving existing formulations, aiming to address gaps in the market and meet the pressing health needs of its population. This commitment to innovation helps Youcare stay abreast of emerging medical trends and continuously expand its product portfolio, which spans from prescription medications to over-the-counter products. The economic engine of Youcare is fueled by a well-integrated supply chain that seamlessly bridges production capabilities with widespread distribution networks. By maintaining control over these critical components, Youcare not only ensures the efficiency and reliability of its delivery but also fortifies its competitive edge in terms of cost and speed to market. This synergy is essential as it allows the company to efficiently manage production costs while adhering to the stringent regulatory standards that govern pharmaceuticals. Revenue streams are further diversified through strategic partnerships and collaborations, which enhance the company’s geographical footprint and market penetration. Consequently, Youcare Pharmaceutical Group not only strengthens its influence domestically but also draws in profits from international markets, establishing itself as a dynamic player in the global pharmaceutical industry.

Intrinsic Value
16.04 CNY
Overvaluation 19%
Intrinsic Value
Price ¥19.8

See Also

What is Youcare Pharmaceutical Group Co Ltd's Total Receivables?
Total Receivables
646m CNY

Based on the financial report for Dec 31, 2025, Youcare Pharmaceutical Group Co Ltd's Total Receivables amounts to 646m CNY.

What is Youcare Pharmaceutical Group Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
-2%

Over the last year, the Total Receivables growth was -24%. The average annual Total Receivables growth rates for Youcare Pharmaceutical Group Co Ltd have been -23% over the past three years , -2% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett